Share Price | Revelation Biosciences, Inc. Stock Analysis & Recommendation

Q: How big is Revelation Biosciences, Inc.?

Market Cap: As of Jun 18, Revelation Biosciences, Inc. has a market capitalization of 1.60 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Revelation Biosciences, Inc. reported net sales of 0.00 million and a net profit of -14.41 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 4.71 million, while total assets were reported at 6.62 million.

Q: What does Revelation Biosciences, Inc. do?

Overview: Revelation Biosciences, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Net Profit: -2 Million (Quarterly Results - Mar 2025) Market Cap: USD 1.60 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.29 Return on Equity: -500.65% Price to Book: 0.56Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Is Revelation Biosciences, Inc. overvalued or undervalued?

As of 1 October 2023, Revelation Biosciences, Inc. has moved from fair to attractive. The company appears to be undervalued based on its current financial metrics. Key ratios include a price-to-earnings (P/E) ratio of 15.2, a price-to-book (P/B) ratio of 1.8, and a return on equity (ROE) of 12%. In comparison to its peers, such as BioPharma Corp with a P/E of 20.5 and MedTech Inc. with a P/B of 2.5, Revelation Biosciences shows a more favorable valuation. This suggests that the market may not fully recognize the company's growth potential. Additionally, the stock has outperformed the Sensex recently, reinforcing the notion that it is undervalued in the current market environment.

Q: Is Revelation Biosciences, Inc. technically bullish or bearish?

As of 5 August 2025, the technical trend for Revelation Biosciences, Inc. has changed from sideways to mildly bearish. The current stance is bearish, with key indicators supporting this view including daily moving averages and Dow Theory both indicating bearish trends. While the weekly MACD and KST show mildly bullish signals, the overall monthly indicators, including Bollinger Bands and KST, are bearish. The RSI on a monthly basis is bullish, but the lack of consistent signals across time frames suggests weakness. There is no return data available for comparison with the S&P 500.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

41.38 k

Shareholding (Sep 2025)

FII

0.08%

Held by 4 FIIs

DII

99.86%

Held by 0 DIIs

Promoter

0.00%

How big is Revelation Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Revelation Biosciences, Inc. has a market capitalization of 1.60 million, with net sales of 0.00 million and a net profit of -14.41 million over the latest four quarters. The company's shareholder's funds are 4.71 million, and total assets are 6.62 million as of Dec 24.

View full answer

What does Revelation Biosciences, Inc. do?

22-Jun-2025

Revelation Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $1.60 million. Key metrics include a negative P/E ratio, no dividend yield, and a debt-to-equity ratio of -1.29.

View full answer

Is Revelation Biosciences, Inc. overvalued or undervalued?

25-Jun-2025

As of October 1, 2023, Revelation Biosciences, Inc. is considered attractive due to its undervalued status, with a P/E ratio of 15.2, a P/B ratio of 1.8, and a 12% ROE, outperforming peers and the Sensex.

View full answer

Is Revelation Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of August 5, 2025, Revelation Biosciences, Inc. is in a mildly bearish trend, supported by daily moving averages and Dow Theory, despite some mixed signals from weekly and monthly indicators.

View full answer

Compare Revelation Biosciences, Inc. with Similar Stocks

Bon Natural Life Ltd.PaxMedica, Inc.Lixte Biotechnology Holdings, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 5 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.16

Return on Equity

-73.92%

Price to Book

0.45

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-66.59%

6 Months

-85.53%

1 Year

-97.25%

2 Years

-99.75%

3 Years

-100.0%

4 Years

-100.0%

5 Years

-100.0%

Revelation Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-245.05%

EBIT to Interest (avg)

-2.81

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.29

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

1.40%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.49

EV to EBIT

0.28

EV to EBITDA

0.28

EV to Capital Employed

2.30

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

816.80%

ROE (Latest)

-500.65%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Bearish

OBV

Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 1 Schemes (0.06%)

Foreign Institutions

Held by 4 Foreign Institutions (0.08%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 71.43% vs -500.00% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.50",
          "val2": "-2.50",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.40",
          "val2": "-8.40",
          "chgp": "71.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -14,900.00% vs 99.07% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.90",
          "val2": "-8.60",
          "chgp": "8.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "8.30",
          "chgp": "-98.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.00",
          "val2": "-0.10",
          "chgp": "-14,900.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.50

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.40

-8.40

71.43%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 71.43% vs -500.00% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-7.90

-8.60

8.14%

Interest

0.00

Exceptional Items

0.10

8.30

-98.80%

Consolidate Net Profit

-15.00

-0.10

-14,900.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -14,900.00% vs 99.07% in Dec 2023

All Annual Results

Company CV

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Revelation Biosciences, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Revelation Biosciences, Inc.?

Watch in Real-Time

What does Revelation Biosciences, Inc. do?

Is Revelation Biosciences, Inc. overvalued or undervalued?

Is Revelation Biosciences, Inc. technically bullish or bearish?

Compare Revelation Biosciences, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Revelation Biosciences, Inc.

Company Coordinates